Our study showed that trichostatin A had the potential to reverse the RR and immune suppression status of HNSCC and might thereby improve the prognosis of HNSCC, providing new bioinformatics evidences on the relationship between HDAC inhibitors and HNSCC. This evidence concerns the gene HDAC9 and head and neck squamous cell carcinoma.